Leaderboard Partners On The Biggest Pharmaceutical Launches in 2024
Leaderboard Branding’s naming & branding experts continue to support the world’s most anticipated launches of 2024.
Firmly established as an agency leader in the pharmaceutical branding space, Leaderboard Branding strengthens partnerships with key clients through strategic initiatives that create ownable and robust global assets.
Charlotte, NC (North Carolina) - Expecting a big 2024, Leaderboard Branding has provided services supporting half of the 10 most anticipated pharmaceutical & biotech launches in 2024.
To support the development of these therapies, Leaderboard’s experts contributed a multitude of services that not only assist in gaining global approval but also help our partners prepare to bring these new treatment options to market. These services include name & brand development, market research, linguistic screenings, and name safety testing.
FiercePharma has identified the following assets as the most anticipated drug launches in 2024 [1]:
karXT - Karuna Therapeutics
Donanemab - Eli Lilly
Resmetiron - Madrigal Pharmaceuticals
Sotatercept - Merck & Co.
Datopotomab deruxtecan - Daiichi Sankyo/AstraZeneca
Acoramidis - BridgeBio Pharma
mRNA - 1345 - Moderna
Anktiva - ImmunityBio
Ensifentrine - Verona Pharma
Imetelstat - Geron
"As Leaderboard continues into our 8th year of operation, it is exciting to see the fruits of our labor with 5 out of the top 10 most anticipated drug launches in 2024. It is a testament to the hard work, strategic thinking, and great partnerships that our team takes pride in that help enable our partners to bring impactful medicines to patients," said Andy Cuykendall, Managing Partner.
To learn more about our work, view more here. To speak with one of our naming & branding experts, contact us.
https://www.fiercepharma.com/special-reports/top-10-most-anticipated-drug-launches-2024